Targeting these interactions may enhance tumor-specific T cell sensitivity and provide an understanding the basis of resistance to PD-1 blockade to potentially allow identification of new molecular targets to enable T cells to overcome dysfunction mediated by multiple inhibitory receptor. The gene discussed is RPL17; the disease is neoplasm.